6 Dec 2017 07:00
6 December 2017
Directorate Change
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the global pharmaceutical and services company, announces that Chris Rigg has resigned with immediate effect as a director to seek a CEO role elsewhere.
Shaun Chilton, CEO of Clinigen, said:
"On behalf of the Board, I would like to thank Chris for his contribution in the first phase of the integration of Quantum Pharma. We wish him well for the future."
-Ends-
Clinigen Group plc | Tel: +44 (0) 1283 495 010 |
Shaun Chilton, Group Chief Executive Officer |
|
|
|
Numis Securities Limited | Tel: +44 (0) 20 7260 1000 |
Michael Meade / Freddie Barnfield (Nominated Adviser)James Black / Tom Ballard (Corporate Broking) |
|
|
|
RBC Capital Markets - Joint Broker | Tel: +44 (0) 20 7653 4000 |
Marcus Jackson / Elliot Thomas / Jack Wood |
|
|
|
Instinctif Partners (media relations) | Tel: +44 (0) 20 7457 2020 |
Melanie Toyne-Sewell / Alex Shaw | Email: clinigen@instinctif.com |
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.
For more information, please visit www.clinigengroup.com